Despite this, in addition to high/amplified cases, there have been promising developments in the treatment of HER2-low (IHC 1+) in breast cancer (51), which may broaden eligibility to these therapies for patients with advanced-stage MOC and HER2 1+ or 2+ on IHC. Here, ERBB2 is linked to breast carcinoma.